European Menopause and Andropause Society

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptom

Retrieved on: 
Thursday, January 26, 2023
European Menopause and Andropause Society, Menopause, North American Menopause Society, Food, Safety, Journal, IVR, Pharmacokinetics, VMS, Harvard Medical School, Estradiol, Estrone, Progesterone, Article, SAN, Clinical trial, FDA, Woman, Plasma, Pharmaceutical industry, IND

SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from a Phase 1 trial evaluating the pharmacokinetics of DARE-HRT1, an investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen, in the journal Menopause, which is the journal of the North American Menopause Society. Daré previously reported positive topline results from this study, as well as from a subsequent Phase 1 / 2 clinical trial of DARE-HRT1. The journal article entitled “Evaluation of 28-Day Estradiol and Progesterone Vaginal Rings in a Phase 1 Clinical Pharmacokinetic Study” is available at the Menopause journal’s website in the Latest Articles section.

Key Points: 
  • Daré previously reported positive topline results from this study, as well as from a subsequent Phase 1 / 2 clinical trial of DARE-HRT1.
  • Hormone therapy is used to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.
  • DARE-HRT1 has the potential to be the first FDA-approved product to offer vaginal delivery of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient monthly format.
  • Ongoing activities to support progressing directly into a single Phase 3 study to support registration include manufacturing and non-clinical studies to support the IND submission and the planned IND-opening Phase 3 study.

Portland State University, PAX and True Terpenes Partner to Develop First-of-its-Kind Open Source Cannabis Framework for Safety Evaluation

Retrieved on: 
Tuesday, January 3, 2023
Science, Public Policy, Government, Other Science, Research, Natural Resources, White House, Federal Government, State, Local, Cannabis, PAX, European Menopause and Andropause Society, Hope, MDPI, Environment, Health, Terpene, Safety, Policy, Cannabis, Doctor of Philosophy, Research, Perfume, Risk management, Drug, Toxicology

However, there is little science-based guidance for consumers, manufacturers, or regulators to evaluate the safety of additives in cannabis concentrates.

Key Points: 
  • However, there is little science-based guidance for consumers, manufacturers, or regulators to evaluate the safety of additives in cannabis concentrates.
  • Ultimately, it aims to increase safety standards across the cannabis industry and, most importantly, reduce consumer risk.
  • However, the federal status of the scheduling of cannabis and divergence across state regulations have created challenges for state-licensed cannabis manufacturers.
  • As the cannabis industry develops, regulators and cannabis manufacturers alike need actionable methods for toxicological risk assessment of inhalable cannabis concentrate additives.

Northwell Holdings and Aegis Ventures Sign Strategic Collaboration Agreement to Launch Upliv, a Comprehensive Digital Health Company for Menopause

Retrieved on: 
Thursday, November 10, 2022
Well, Aegis, Northwell Health, Love, Health, European Menopause and Andropause Society, Hofstra University, Health care, Women's health, Menopause, Intelligence, Holding, Weight gain, Intention, Flash, Total, Neurology, Psychiatry, Fatigue, Practitioner, Brain, NAMS, Patient, Myalgia, Solution, Time, Senior, Nursing, Gaps, Life, Woman, North American Menopause Society, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Cardiology, National Board of Health and Welfare (Sweden), Health insurance, Cryptocurrency, Pharmaceutical industry, Medicine, Management

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Northwell Holdings and Aegis Ventures inked an agreement today for the formation of Upliv, a women's virtual care start-up that aims to raise the bar for clinical menopause support. Upliv will partner with employers to offer virtual telemedicine services and whole-person care to employees experiencing perimenopause and menopause symptoms. Initially, Upliv will offer services to select nurses through a pilot program at Northwell Health, followed by an expected enterprise-wide rollout in the first quarter of 2023.

Key Points: 
  • Upliv is the joint creation of Aegis Ventures and Northwell Holdings, the for-profit investment arm of Northwell Health.
  • In April 2022, Aegis Ventures announced the intention to invest at least $100 million in seed-stage funds towards the development of joint ventures with Northwell Health.
  • Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies.
  • Through strategic partnerships, Holdings leverages the health system's robust enterprise data assets to develop AI-enabled solutions that address healthcare inequities.

Dr. Jane Goodall and Vivodyne Issue Open Letter to Congressional Leaders to Include FDA Modernization Act as a Rider in the Food and Drug Amendments Act of 2022

Retrieved on: 
Thursday, September 8, 2022
Research, Pharmaceutical, White House, Federal Government, Animal Welfare, Healthcare Reform, Science, Veterinary, Biotechnology, FDA, Congressional News, Views, Health, Public Policy, Government, Jane Goodall, Human, Safety, Cancer, Research, FFDCA, Vaccine, Food and Drug Administration Modernization Act of 1997, Disease, Tissue, Mouse, Letter, Stem cell, Food, Intelligence, MPS, Education, Animal, New, Jane Goodall Institute, FDA, Therapy, Founder, Risk, European Menopause and Andropause Society, Congress, DBE, Health, Patient, Pharmaceutical industry, Medical device

We cannot continue to vainly expect caged animals to accurately predict human drug responses.

Key Points: 
  • We cannot continue to vainly expect caged animals to accurately predict human drug responses.
  • Mandating that such promising drugs are tested on animals where they are guaranteed to fail, will only inhibit their further development.
  • Importantly, these modern approaches do not rely on the use of embryonic stem cells or other materials that raise ethical concerns.
  • We thank you and appreciate your support for the FDA Modernization Act by including it in the FDA User Fee package.

US Fertility welcomes reproductive endocrinologist, Johanna Archer, V.M.D., M.S., M.D., to the Shady Grove Fertility (SGF) Jones Institute physician team

Retrieved on: 
Tuesday, August 16, 2022
European Menopause and Andropause Society, Reproductive medicine, Perelman School of Medicine at the University of Pennsylvania, Fertility, Endometriosis, University of California, Irvine Medical Center, Eastern Virginia Medical School, Polycystic ovary syndrome, IVF, Cancer, Infertility, School, ACOG, SGF, Research, Society, Obstetrics, American College, Patient, North American Menopause Society, Primary ovarian insufficiency, Partnership, American Society for Reproductive Medicine, ASRM, PCOS, REI, Insurance, University, POI, NAMS, Veterinary medicine, Medical University of South Carolina, Medical school, University of Wisconsin–Madison, Cummings School of Veterinary Medicine, American College of Obstetricians and Gynecologists, Medicine, Medical device, Gynaecology, MD

NORFOLK, Va., Aug. 16, 2022 /PRNewswire-PRWeb/ -- US Fertility, the nation's largest partnership of physician-owned and physician-led top-tier fertility practices, welcomes Johanna Archer, V.M.D., M.S., M.D., to Shady Grove Fertility's (SGF) Jones Institute in Norfolk, Virginia. Dr. Archer is now scheduling new patient appointments.

Key Points: 
  • She then completed her residency in OB/GYN at the Medical University of South Carolina in Charleston, South Carolina.
  • From there, Dr. Archer trained in REI at the University of California in San Diego, California.
  • During this time, Dr. Archer was recognized for her excellence in research by the American Society for Reproductive Medicine (ASRM).
  • SGF is among the founding partner practices of US Fertility , the largest physician-led partnership of top-tier fertility practices in the U.S.

Andy Nong Joins ScitoVation as Director of Computational Toxicology

Retrieved on: 
Monday, July 11, 2022
Partnership, Nong, Economy, Toxicology, Risk assessment, Chemical industry, CEO, NAS, National Academies of Sciences, Engineering, and Medicine, Industry, NAM, Ecosystem, Doctor of Philosophy, Outline of health sciences, Household, Publication, University, Minister of Health (Canada), Environment, Exposure, European Menopause and Andropause Society, Organisation for Economic Co-operation and Development controversy, Chemical safety, Drinking water, Organization, National Institute of Environmental Health Sciences, Society, Public health, Research, Journal, OECD, Editing, Université de Montréal, Board, Laboratory, State Research Bureau (organisation), Health Canada, National academy, Management, Medical device, Development

DURHAM, N.C., July 11, 2022 /PRNewswire-PRWeb/ -- ScitoVation announced today the new Director of Computational Toxicology, Andy Nong PhD, formerly Health Canada's Acting Manager of the Exposure and Biomonitoring Division and Principal Research Scientist for the Computational Toxicology Laboratory of the Environmental Health Sciences and Research Bureau.

Key Points: 
  • DURHAM, N.C., July 11, 2022 /PRNewswire-PRWeb/ -- ScitoVation announced today the new Director of Computational Toxicology, Andy Nong PhD, formerly Health Canada's Acting Manager of the Exposure and Biomonitoring Division and Principal Research Scientist for the Computational Toxicology Laboratory of the Environmental Health Sciences and Research Bureau.
  • Dr Nong is excited to join ScitoVation and lead its excellent computational experts.
  • He explained, "I am thrilled to become part of the talented Scitovation team and provide guidance on computational research for New Approach Methods (NAM).
  • In addition to his research activities, Dr Nong is the former past president for the Society of Toxicology Biological Modeling Speciality Section.

PCCA’s compounding pharmacist members call on Congress to protect patient access to compounded medication

Retrieved on: 
Thursday, May 12, 2022
ACT, PCCA, Risk, Education, Communication, Compound, Doctor of Pharmacy, Food, CBHT-DT, Fear, Doctor of Philosophy, Food and Drug Administration, Patient, Science, Woman, Meta-analysis, North American Menopause Society, Pharmacist, Prescription, Pharmacy, NAMS, FDA, National Academies of Sciences, Engineering, and Medicine, GFI, Conference, MS, Systematic review, Man, Congress, Safety, Compounding, Hormone, European Menopause and Andropause Society, NASEM, Public affairs, National academy, GLOBE, Pharmaceutical industry, Menopause, Medicine, Industry, Engineering

Houston, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Compounding pharmacists nationwide are calling on lawmakers to thwart efforts that pharmacists fear would restrict patient access to compounded medications.

Key Points: 
  • Houston, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Compounding pharmacists nationwide are calling on lawmakers to thwart efforts that pharmacists fear would restrict patient access to compounded medications.
  • This method allows the compounding pharmacist to work with the patient and the prescriber to customize a medication to meet the patients specific needs.
  • More than 60 compounders are participating in this years conference to share critical patient access issues centering around compounded hormones and animal patient compounded medications with members of Congress.
  • If implemented, these recommendations would restrict or eliminate patient access to compounded hormones, negatively impacting millions of women and men nationwide.

Phenology, a New Women's Health Brand From the Team at Hologram Sciences, is the One-Stop Destination for Menopause

Retrieved on: 
Monday, May 2, 2022
ACT, Cream, Hope, Phenology, American College, Brain, American Board of Commissioners for Foreign Missions, Woman, Sleep, Neck, Food, Food and Drug Administration, American Board of Obstetrics and Gynecology, Menopause, Genistein, Gynaecology, North American Menopause Society, Skin, Multimedia, Face, Health, Chief Medical Advisor to the President, Plant, Disease, CBD, European Menopause and Andropause Society, Biology, Obstetrics, Pub, Caffeine, Sensation, Progesterone, Collection, Mood Swings, Hyaluronic acid, Flash, Medicine, Birth control, Pharmaceutical industry, Dietary supplement

So, it's no surprise that women in menopause often feel isolated, stressed, and struggle to find relief.

Key Points: 
  • So, it's no surprise that women in menopause often feel isolated, stressed, and struggle to find relief.
  • "We deserve evidence-based, scientific solutions and meaningful innovations to support this journey and also deserve to have an affirming experience.
  • "This approach more holistically addresses the health and beauty symptoms that women experience as a result of the hormonal changes associated with menopause."
  • Phenology is a personalized women's health initiative that delivers timely relief and expert guidance through each stage and symptom of menopause.

ScitoVation Nabs Leslie Recio, PhD DABT, as Chief Scientific Officer

Retrieved on: 
Thursday, April 28, 2022
ILS, University, CEO, Pacific Economic Cooperation Council, Genetic, Toxicological Sciences, DABT, Leadership, Method, European Menopause and Andropause Society, ISCB Senior Scientist Award, Organization, Environmental Mutagenesis and Genomics Society, Society, Partnership, OECD, Principal, GEMS, Biomarker, Animal, Genetics, SOT, Editing, Research, Hepatocyte, NAM, Doctor of Philosophy, MIT, Council, Risk, Black Panther Party, Winston-Salem, North Carolina Chapter, National Toxicology Program, Mutagen, American Board of Commissioners for Foreign Missions, NTP, Society of Toxicology, Medical device, Management, Mutagenesis, Microbiology, Toxicology

DURHAM, N.C., April 28, 2022 /PRNewswire-PRWeb/ -- ScitoVation is pleased to announce Leslie Recio, PhD, DABT, as the new Chief Scientific Officer. Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS. Dr. Recio will help lead the team of Senior Scientists, drive priorities in New Approach Methods and help secure new business ventures.

Key Points: 
  • Dr. Recio joins ScitoVation as the Chief Scientific Officer to drive priorities in New Approach Methods and help secure new business ventures.
  • DURHAM, N.C., April 28, 2022 /PRNewswire-PRWeb/ -- ScitoVation is pleased to announce Leslie Recio, PhD, DABT, as the new Chief Scientific Officer.
  • Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS.
  • Dr. Recio has over 30 years of experience in toxicology research in the areas of mutagenesis, toxicogenomics, and regulatory genotoxicity assessments.

$16+ Billion Worldwide Drugs For Hormonal Replacement Therapy Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 11, 2021
General Health, Pharmaceutical, Health, Benchmark, Menopause, Population, Nausea, Hormone, Pharmacy, HGH, Female, Industry, Vaginal bleeding, European Menopause and Andropause Society, Estradiol (medication), Extrapyramidal system, Ageing, International Menopause Society, Coronavirus, Bloating, Growth, Vagina, Thrombus, Estrogen patch, Personal lubricant, Hypogonadism, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Kent, Woman, Stomach, Cardiovascular disease, HRT, Novo Nordisk, Create, Hypothyroidism, Breast cancer, Male, EMAS, Osteoporosis, Indigestion, Marketing, Birth control

Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.

Key Points: 
  • Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.
  • Thus, the increasing side effects of drugs hinders the growth of drugs for hormonal replacement therapy.
  • Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth.
  • Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market.